8-K: Orchestra BioMed Secures $21M from Vivasure Acquisition

Orchestra BioMed expects to receive up to $21 million in proceeds from the acquisition of its strategic holding, Vivasure Medical, by Haemonetics Corporation.

Summary

• Orchestra BioMed Holdings, Inc. (OBIO) announced it expects to receive up to $21 million in cash proceeds from the acquisition of Vivasure Medical Limited by Haemonetics Corporation.
• Vivasure Medical, a company pioneering next-generation technology for percutaneous vessel closure, was a strategic holding of Orchestra BioMed.
• The acquisition of Vivasure by Haemonetics closed on January 9, 2026.
• Orchestra BioMed anticipates receiving $11 million of these proceeds in 2026, comprising approximately $5 million upfront and approximately $6 million as a first milestone payment.
• The remaining proceeds are contingent on future revenue earnouts based on the achievement of certain milestones.
• Vivasure's PerQseal Elite system, which uses a proprietary bioabsorbable patch for large-bore vessel closure, received CE Mark approval in Europe for arterial and venous indications and submitted a Premarket Approval application to the U.S. FDA in 2025.
• Clinical results from the ELITE arterial study for PerQseal Elite demonstrated ease of use, 0% major complications at 30-day follow-up, and immediate median time to hemostasis.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant cash inflow from the successful realization of a strategic investment, validating Orchestra BioMed's partnership model and providing capital for its ongoing pipeline development. While some proceeds are contingent, the immediate $11 million is a strong positive.

Positives

• Expected cash inflow of up to $21 million provides capital for Orchestra BioMed's operations and pipeline development.
• The transaction validates Orchestra BioMed's strategy of accelerating high-impact technologies through risk-reward sharing partnerships.
• Vivasure's PerQseal Elite system demonstrated strong clinical results, including 0% major complications at 30-day follow-up, positioning it as a best-in-class solution.
• The successful exit from a strategic holding demonstrates effective portfolio management and value creation.

Negatives

• A portion of the total expected proceeds (up to $10 million) is contingent on future revenue earnouts and milestone achievements, introducing an element of uncertainty regarding the full realization of the $21 million.

Risks

• Actual events and circumstances may differ from assumptions, and many are beyond the control of the Company.
• Changes in domestic and foreign business, market, financial, political, and legal conditions could impact future performance.
• Risks related to regulatory approval of the Company's commercial product candidates and ongoing regulation of product candidates, if approved.
• The timing of, and the Company's ability to achieve expected regulatory and business milestones.
• The impact of competitive products and product candidates in the rapidly changing and competitive environment.
• The Company operates in a very competitive and rapidly changing environment, with new risks emerging over time.

Future Outlook

Orchestra BioMed expects to receive the remainder of the up to $21 million in proceeds through future revenue earnouts based on the achievement of certain milestones. The company continues to advance its two flagship product candidates, AVIM Therapy and Virtue Sirolimus AngioInfusion Balloon, which are currently undergoing pivotal clinical trials for their lead indications.

Management Comments

• David Hochman, Chairman and CEO of Orchestra BioMed, stated: "Vivasure has been a strategic holding since the formation of Orchestra BioMed, and we have been active and intentional in supporting the company for many years. We are very proud of the outstanding clinical results from the PerQseal product platform which we believe clearly positions it as a best-in-class solution for large diameter percutaneous vessel closure. This transaction represents a clear realization of our preferred approach to device development, powered by long-term, strategically aligned partnerships."
• Andrew Glass, CEO of Vivasure Medical Limited, commented: "Orchestra BioMed has been a deeply engaged partner since the earliest days of Vivasure. Their co-founders helped to lead our initial financing and supported the development of our PerQseal technology from concept stage. With Orchestra BioMed CEO, David Hochman, serving as an active board observer since 2019, and COO, Darren Sherman as an original board member through 2016, their strategic insight and guidance contributed meaningfully to the development of our product and its evolution to this next chapter."
• Rajeev Varma, Senior Vice President, Strategy and Corporate Development of Haemonetics, said: "Vivasure has built a clinically differentiated closure device technology with PerQseal Elite, supported by strong clinical performance and safety data, representing a compelling opportunity to strengthen our impact in the large-bore closure market and structural heart and endovascular procedures."

Industry Context

This acquisition highlights ongoing consolidation and strategic investments within the medical technology sector, particularly in specialized areas like percutaneous vessel closure. Haemonetics' acquisition of Vivasure strengthens its position in the large-bore closure market and expands its offerings in structural heart and endovascular procedures. For Orchestra BioMed, the transaction validates its model of partnering with and investing in innovative biomedical companies, demonstrating a successful exit from a strategic holding.

Comparison to Industry Standards

• Vivasure's PerQseal Elite system is positioned as a 'best-in-class solution' for large diameter percutaneous vessel closure, supported by clinical results from the ELITE arterial study.
• The ELITE arterial study demonstrated 'ease of use with no need for pre-close,' '0% major complications at 30-day follow-up,' and 'immediate median time to hemostasis,' indicating strong performance compared to existing closure devices which may have higher complication rates or require more complex procedures.

Related Party Transactions

• Vivasure Medical Limited was a strategic holding of Orchestra BioMed since the Company's formation, with Orchestra BioMed's CEO and COO having active roles as a board observer and original board member, respectively, indicating a close relationship prior to the acquisition.

Stakeholder Impact

• Shareholders of Orchestra BioMed are likely to benefit from the cash proceeds, which can strengthen the company's financial position and support future growth initiatives.
• Employees of Vivasure Medical Limited will now be part of Haemonetics Corporation, potentially benefiting from the resources and scale of a larger medical technology company.

Next Steps

• Haemonetics Corporation will take the PerQseal product platform forward commercially.
• Orchestra BioMed will continue to advance its flagship product candidates, AVIM Therapy and Virtue Sirolimus AngioInfusion Balloon, through pivotal clinical trials for their lead indications.

Key Dates

Recommendation

The receipt of up to $21 million in proceeds from the Vivasure acquisition is a significant positive, validating Orchestra BioMed's strategic investment model and bolstering its cash reserves. This reduces near-term financial risk and provides capital for its core pipeline (AVIM Therapy and Virtue SAB). However, the company's long-term value remains largely tied to the successful development and commercialization of these core product candidates, which are still in pivotal clinical trials. While the cash inflow is beneficial, it represents the realization of a past investment rather than a fundamental shift in the operational outlook of its primary business. Therefore, a 'hold' recommendation is appropriate for investors to observe the progress of its flagship products, as the current news is a positive event but doesn't fundamentally alter the risk/reward profile of its core R&D-heavy business.

Keywords

Orchestra BioMed, Vivasure Medical, Haemonetics, Acquisition, Proceeds, Medical Device, Percutaneous Vessel Closure, Strategic Holding, Biomedical Innovation, AVIM Therapy, Virtue SAB, FDA Breakthrough Device Designation, CE Mark